ASH 2018 | MAIA trial: addition of daratumumab to Rd in newly diagnosed transplant-ineligible MM
Thierry Facon
• 6 Dec 2018
Thierry Facon, MD, Claude Huriez Hospital, Lille, France, presents the interim results of the Phase III MAIA trial (NCT02252172), which evaluated the addition of daratumumab to lenalidomide/dexamethasone (D-Rd) vs. Rd alone in transplant-ineligible newly diagnosed multiple myeloma (NDMM). The D-Rd regimen significantly reduced the risk of progression or death, with no new safety signals. Combined with the results of the ALCYONE study (D-VMP vs. VMP; NCT02195479), these data support the addition of daratumumab to the standard of care in transplant-ineligible NDMM. This video was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
